281 related articles for article (PubMed ID: 29338306)
1. Biomarkers for assessing the effectiveness of immunotherapy in breast cancer.
Nixon MJ; Balko JM
Biomark Med; 2018 Feb; 12(2):97-100. PubMed ID: 29338306
[No Abstract] [Full Text] [Related]
2. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
3. Defining the immunogram of breast cancer: a focus on clinical trials.
Tarantino P; Curigliano G
Expert Opin Biol Ther; 2019 May; 19(5):383-385. PubMed ID: 30892954
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint Inhibitors in the Treatment of Breast Cancer.
Lyons TG; Dickler MN; Comen EE
Curr Oncol Rep; 2018 Apr; 20(7):51. PubMed ID: 29713831
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
6. PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study.
Ács B; Madaras L; Tőkés AM; Kovács AK; Kovács E; Ozsvári-Vidákovich M; Karászi Á; Birtalan E; Dank M; Szász AM; Kulka J
Breast; 2017 Oct; 35():69-77. PubMed ID: 28651116
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
8. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Kassardjian A; Shintaku PI; Moatamed NA
PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in triple-negative breast cancer.
Katz H; Alsharedi M
Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
[TBL] [Abstract][Full Text] [Related]
11. Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?
Zito Marino F; Ascierto PA; Rossi G; Staibano S; Montella M; Russo D; Alfano R; Morabito A; Botti G; Franco R
Expert Opin Biol Ther; 2017 Jun; 17(6):735-746. PubMed ID: 28318336
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
13. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
14. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
15. Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer.
Jang BS; Han W; Kim IA
Radiother Oncol; 2020 Jan; 142():202-209. PubMed ID: 31767471
[TBL] [Abstract][Full Text] [Related]
16. [PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer].
Monneur A; Gonçalves A; Bertucci F
Bull Cancer; 2018 Mar; 105(3):263-274. PubMed ID: 29455872
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.
Bertucci F; Gonçalves A
Curr Oncol Rep; 2017 Aug; 19(10):64. PubMed ID: 28799073
[TBL] [Abstract][Full Text] [Related]
18. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
19. The Role of Biomarkers for the Prediction of Response to Checkpoint Immunotherapy and the Rationale for the Use of Checkpoint Immunotherapy in Cervical Cancer.
Otter SJ; Chatterjee J; Stewart AJ; Michael A
Clin Oncol (R Coll Radiol); 2019 Dec; 31(12):834-843. PubMed ID: 31331818
[TBL] [Abstract][Full Text] [Related]
20. Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.
Stovgaard ES; Nielsen D; Hogdall E; Balslev E
Acta Oncol; 2018 Jan; 57(1):74-82. PubMed ID: 29168430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]